TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00738179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP worn nightly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care of cardiovascular risk factors
Study: NCT03686605

Intervention type: OTHER
Intervention: Thai version of the Edmontom Symptom Assessment System (ESAS)
Description: Screening and diagnostic questionaire for depression
Study: NCT01025882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Given as a single fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Given as a single fraction
Study: NCT04230928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 \& 10. Participants will learn to track carbohydrate intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard DPP-GLB diet
Description: Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, \& 10

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard DPP-GLB program modules
Description: Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard DPP-GLB program modules
Description: Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
Study: NCT03982732

Intervention type: BIOLOGICAL
Intervention: Boostrix-IPV
Description: Receipt of Boostrix IPV at three different gestational time periods

Intervention type: BIOLOGICAL
Intervention: Boostrix-IPV
Description: Receipt of Boostrix IPV at three different gestational time periods

Intervention type: BIOLOGICAL
Intervention: Boostrix-IPV
Description: Receipt of Boostrix IPV at three different gestational time periods
Study: NCT00469430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefotaxim and metronidazol
Description: iv administration for at least 24 h
Study: NCT03095729

Intervention type: OTHER
Intervention: Neuropsychological tests
Description: A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)

Intervention type: OTHER
Intervention: Neuropsychological tests
Description: A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
Study: NCT01792037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Study: NCT05800886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization and tea consumption
Description: At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization and coffee consumption
Description: At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization and warm water consumption
Description: At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ongoing treatment
Description: The first mobilization and oral intake of the patients in the control group started at the 8th hour.
Study: NCT01582035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
Study: NCT01792037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT01582035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVR
Description: type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
Study: NCT01792037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study: NCT01807299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega 3
Description: Capsules of omega 3, 1000mg / capsules. Administered 3 times a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Training
Study: NCT03057015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
Study: NCT01582035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegFN
Description: type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegFN
Description: type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
Study: NCT03057015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study: NCT01582035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
Study: NCT03057015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study: NCT00404287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvastatin
Study: NCT03057015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine
Description: Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
Study: NCT01789684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Provider Intervention
Description: Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
Study: NCT03800238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Delivery Format
Description: Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Delivery Format
Description: Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
Study: NCT00681889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 10 Patients will receive treatment (Ranibizumab)
Study: NCT04406675

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological test
Description: neuropsychological test

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological test
Description: neuropsychological test
Study: NCT03221686

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: High quality protein supplement 14 days pre-operatively and post-operatively.
Study: NCT00939536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem Tartrate Tablets 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate Tablets 10 mg
Study: NCT02106871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: 50mg of Sildenafil daily for 4 weeks
Study: NCT02046993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Encouraged to do HBP measurement and record BP readings in paper diary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Encouraged to do HBP measurement and record BP readings in paper diary
Study: NCT02062541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funct. assessment+fast rehabilitation
Study: NCT00404287

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluvastatin
Study: NCT02000726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
Description: Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
Study: NCT02062541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funct. assessment+usual rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual assessment+fast rehabilitation
Study: NCT01343238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 12 week diet behavior modification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week exercise behavioral intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: 12 week diet and exercise behavioral modification intervention
Study: NCT03890133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Description: Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear.
Study: NCT02106871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50mg of Sildenafil daily for 4 weeks
Study: NCT03771651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
Study: NCT03507673

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and microbiological swaps
Description: Blood analysis and analysis of vaginal microbiota.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and microbiological swaps
Description: Blood analysis and analysis of vaginal microbiota.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and microbiological swaps
Description: Blood analysis and analysis of vaginal microbiota.
Study: NCT01653522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptan
Study: NCT03507673

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and microbiological swaps
Description: Blood analysis and analysis of vaginal microbiota.
Study: NCT01131910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE-vaccine
Description: Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBE-vaccine
Description: Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination against TBE
Description: 0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
Study: NCT01965730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epsilon-aminocaproic acid (EACA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epsilon-aminocaproic acid (EACA)
Study: NCT03005132

Intervention type: OTHER
Intervention: Normal brain tissue
Description: The investigators will extract total protein, DNA and RNA from the samples.

Intervention type: OTHER
Intervention: Normal brain tissue
Description: The investigators will extract total protein, DNA and RNA from the samples.

Intervention type: OTHER
Intervention: Normal brain tissue
Description: The investigators will extract total protein, DNA and RNA from the samples.
Study: NCT00746863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125% Marcaine
Description: Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
Study: NCT03094117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT02475278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV GI.1/GII.4 Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
Study: NCT01653522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study: NCT00640510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid Acting Intramuscular Olanzapine
Description: 10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic sodium chloride solution
Description: 0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
Study: NCT02163291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel liposome
Description: S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
Study: NCT02243150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T28-1 (CDK 4/6 Inhibitor)
Study: NCT03890133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsule
Description: Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
Study: NCT02818582

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5734
Description: Daily GS-5734 delivered intravenously (IV) for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo delivered intravenously (IV) for 5 days.
Study: NCT05390060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring
Description: Multimodal neuromonitoring encompassing intracranial pressure, brain tissue oxygenation, microdialysis and cerebral blood flow monitoring
Study: NCT02223624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking and light weights

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking and light weights

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric aerobic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concentric aerobic exercise
Study: NCT00401310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo IV infusions 1hr/daily over 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0724
Description: MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
Study: NCT03948321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid photodynamic therapy
Description: Aminolevulinic acid photodynamic therapy
Study: NCT02353234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: In each arm subjects consume bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: In each arm subjects consume bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: In each arm subjects consume bread
Study: NCT03088566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The D-Foot method
Description: The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional foot screening
Description: The foot screening is performed with clinical conventional methods.